{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:48:44Z","timestamp":1787788124418,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immunohistochemical detection of prostate specific antigen (PSA) is widely used to identify metastatic prostatic adenocarcinoma. However, PSA may not be expressed in some poorly differentiated prostatic carcinomas and its immunoreactivity has been found in some non-prostatic tissues. P501s (prostein) is a prostate-specific marker that is expressed in the cytoplasm of benign and malignant prostatic glandular cells. It has not been detected in any other normal or malignant tissues. The purpose of this study was to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare its expression with PSA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Immunohistochemical stains with anti-P501s antibodies were performed on 5-micron sections of tissue microarray (TMA) specimens. The TMA is constructed with normal donor prostates (NDP), prostatic adenocarcinoma (PRCA), non-neoplastic prostatic tissues adjacent to malignant glands (NAT), benign prostatic hyperplasia (BPH), high-grade prostatic neoplasia (PIN), metastatic adenocarcinoma to lymph nodes (MLN), metastatic adenocarcinoma to other sites (MC), and samples of benign testis, colon, adrenal and kidney. The two groups of metastatic lesions were also subjected to stains with antibodies to PSA. A composite score (ranging from 0 to 3) was assigned to score intensity of staining.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Granular staining pattern of p501s was seen in all benign glands (score = 1.77 \u2013 2.1) and malignant acini (score = 1.52) at the apical aspect of cytoplasm, predominantly adjacent to the nuclei. No staining was observed in controls including testis, colon, adrenal and kidney. The MLN group received a score of 1.0, with 10% of cases negative for p501s. The MC cases had a score of 0.64, with 16.7% of case showing loss of p501s expression. Although the metastatic lesions demonstrated similar rate of negative expression with PSA antibody, only 2 MC cases (3.3%) showed simultaneous negative stains for both P501S and PSA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>P501s is an organ specific marker for benign and malignant prostatic epithelial cells. Its characteristic cytoplasmic stain pattern provides an additional valuable immunomarker for detection of metastatic prostatic malignancy, even though the intensity of its expression is reduced, as in the case with PSA. Simultaneous stains with P501S and PSA will greatly improve the detection rate and identify a significant majority of the metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1746-1596-2-41","type":"journal-article","created":{"date-parts":[[2007,10,27]],"date-time":"2007-10-27T04:39:42Z","timestamp":1193459982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma"],"prefix":"10.1186","volume":"2","author":[{"given":"Ming","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,27]]},"reference":[{"key":"87_CR1","first-page":"162","volume-title":"WHO Classification of Tumours: Pathology and genetics of tumours of the urinary system and male genital organs","author":"JI Epstein","year":"2004","unstructured":"J.I. Epstein FA W.C. Allsbrook Jr., S. Bastacky, L. Boccon-Gibod, A.M. De Marzo, L. Egevad, M. Furusato,, Hamper UM: Acinar adenocarcinoma. In WHO Classification of Tumours: Pathology and genetics of tumours of the urinary system and male genital organs Edited by: John N. Eble GSJIEIAS. Lyon , IARC Press; 2004:162."},{"issue":"1","key":"87_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.49.1.8","volume":"49","author":"SH Landis","year":"1999","unstructured":"Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin. 1999, 49 (1): 8-31, 1.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"87_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF01758959","volume":"3","author":"S Plesnicar","year":"1985","unstructured":"Plesnicar S: The course of metastatic disease originating from carcinoma of the prostate. Clin Exp Metastasis. 1985, 3 (2): 103-110. 10.1007\/BF01758959.","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"87_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00405-006-0066-2","volume":"263","author":"K Hematpour","year":"2006","unstructured":"Hematpour K, Bennett CJ, Rogers D, Head CS: Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer. Eur Arch Otorhinolaryngol. 2006, 263 (9): 872-874. 10.1007\/s00405-006-0066-2.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5 Pt 2","key":"87_CR5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0022-5347(17)32370-4","volume":"152","author":"JI Epstein","year":"1994","unstructured":"Epstein JI, Walsh PC, Brendler CB: Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol. 1994, 152 (5 Pt 2): 1721-1729.","journal-title":"J Urol"},{"issue":"3","key":"87_CR6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-5347(17)36131-1","volume":"149","author":"TA Stamey","year":"1993","unstructured":"Stamey TA, Dietrick DD, Issa MM: Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol. 1993, 149 (3): 510-515.","journal-title":"J Urol"},{"issue":"3","key":"87_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00295844","volume":"18","author":"MP Gallee","year":"1990","unstructured":"Gallee MP, Visser-de Jong E, van der Korput JA, van der Kwast TH, ten Kate FJ, Schroeder FH, Trapman J: Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res. 1990, 18 (3): 181-187. 10.1007\/BF00295844.","journal-title":"Urol Res"},{"issue":"2","key":"87_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000472463","volume":"11","author":"J Steffens","year":"1985","unstructured":"Steffens J, Friedmann W, Lobeck H: Immunohistochemical diagnosis of the metastasizing prostatic carcinoma. Eur Urol. 1985, 11 (2): 91-94.","journal-title":"Eur Urol"},{"issue":"3","key":"87_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/1097-0339(200009)23:3<199::AID-DC12>3.0.CO;2-4","volume":"23","author":"AA Renshaw","year":"2000","unstructured":"Renshaw AA, Granter SR: Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration. Diagn Cytopathol. 2000, 23 (3): 199-201. 10.1002\/1097-0339(200009)23:3<199::AID-DC12>3.0.CO;2-4.","journal-title":"Diagn Cytopathol"},{"issue":"11","key":"87_CR10","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998, 82 (11): 2256-2261. 10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S.","journal-title":"Cancer"},{"issue":"7","key":"87_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0046-8177(03)00190-4","volume":"34","author":"MP Roudier","year":"2003","unstructured":"Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL: Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003, 34 (7): 646-653. 10.1016\/S0046-8177(03)00190-4.","journal-title":"Hum Pathol"},{"issue":"2","key":"87_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/(SICI)1097-0045(19970501)31:2<91::AID-PROS3>3.0.CO;2-K","volume":"31","author":"G Ljung","year":"1997","unstructured":"Ljung G, Norberg M, Holmberg L, Busch C, Nilsson S: Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. Prostate. 1997, 31 (2): 91-97. 10.1002\/(SICI)1097-0045(19970501)31:2<91::AID-PROS3>3.0.CO;2-K.","journal-title":"Prostate"},{"issue":"3","key":"87_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajcp\/81.3.279","volume":"81","author":"DW Ellis","year":"1984","unstructured":"Ellis DW, Leffers S, Davies JS, Ng AB: Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol. 1984, 81 (3): 279-284.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"87_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/jcp.2004.018291","volume":"58","author":"PJ Carder","year":"2005","unstructured":"Carder PJ, Speirs V, Ramsdale J, Lansdown MR: Expression of prostate specific antigen in male breast cancer. J Clin Pathol. 2005, 58 (1): 69-71. 10.1136\/jcp.2004.018291.","journal-title":"J Clin Pathol"},{"issue":"2 Pt 1","key":"87_CR15","first-page":"464","volume":"156","author":"AA Elgamal","year":"1996","unstructured":"Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol. 1996, 156 (2 Pt 1): 464-468.","journal-title":"J Urol"},{"issue":"2","key":"87_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1006210627219","volume":"56","author":"KA Alanen","year":"1999","unstructured":"Alanen KA, Kuopio T, Collan YU, Kronqvist P, Juntti L, Nevalainen TJ: Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat. 1999, 56 (2): 169-176. 10.1023\/A:1006210627219.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"87_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1097-0339(199809)19:3<221::AID-DC14>3.0.CO;2-G","volume":"19","author":"GF Holmes","year":"1998","unstructured":"Holmes GF, Eisele DW, Rosenthal D, Westra WH: PSA immunoreactivity in a parotid oncocytoma: a diagnostic pitfall in discriminating primary parotid neoplasms from metastatic prostate cancer. Diagn Cytopathol. 1998, 19 (3): 221-225. 10.1002\/(SICI)1097-0339(199809)19:3<221::AID-DC14>3.0.CO;2-G.","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"87_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/eji.200324768","volume":"34","author":"RS Friedman","year":"2004","unstructured":"Friedman RS, Spies AG, Kalos M: Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol. 2004, 34 (4): 1091-1101. 10.1002\/eji.200324768.","journal-title":"Eur J Immunol"},{"issue":"4","key":"87_CR19","first-page":"1563","volume":"61","author":"J Xu","year":"2001","unstructured":"Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, Filho AM, Nolasco M, Badaro R, Reed SG: Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001, 61 (4): 1563-1568.","journal-title":"Cancer Res"},{"issue":"5","key":"87_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjc.6601642","volume":"90","author":"A Kiessling","year":"2004","unstructured":"Kiessling A, Stevanovic S, Fussel S, Weigle B, Rieger MA, Temme A, Rieber EP, Schmitz M: Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. Br J Cancer. 2004, 90 (5): 1034-1040. 10.1038\/sj.bjc.6601642.","journal-title":"Br J Cancer"},{"issue":"3","key":"87_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/pros.20043","volume":"60","author":"M Kalos","year":"2004","unstructured":"Kalos M, Askaa J, Hylander BL, Repasky EA, Cai F, Vedvick T, Reed SG, Wright GL, Fanger GR: Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004, 60 (3): 246-256. 10.1002\/pros.20043.","journal-title":"Prostate"},{"issue":"2","key":"87_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10735-006-9054-5","volume":"38","author":"A Kajdacsy-Balla","year":"2007","unstructured":"Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, Orenstein J, Bayerl J, Becich MJ, Dhir R, Datta MW: Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol. 2007, 38 (2): 113-121. 10.1007\/s10735-006-9054-5.","journal-title":"J Mol Histol"},{"issue":"10","key":"87_CR23","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.3748\/wjg.v9.i10.2202","volume":"9","author":"P Zhao","year":"2003","unstructured":"Zhao P, Hu YC, Talbot IC: Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol. 2003, 9 (10): 2202-2206.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"87_CR24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5858\/2007-131-599-DPFCAO","volume":"131","author":"CL Owens","year":"2007","unstructured":"Owens CL, Epstein JI, Netto GJ: Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. Arch Pathol Lab Med. 2007, 131 (4): 599-603.","journal-title":"Arch Pathol Lab Med"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-2-41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:41:38Z","timestamp":1630453298000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-2-41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-2-41","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,27]]},"assertion":[{"value":"16 June 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"41"}}